Glivec er indiceret til behandling af • voksne og børn med nydiagnosticeret Philadelphiakromosom (bcr- abl) positiv (Ph+) kronisk myeloid leukæmi (CML), for hvilke knoglemarvstransplantation ikke anses for førstevalgsbehandling. • voksne og børn med Ph+ CML i kronisk fase efter manglende effekt af alfa - interferonbehandling, eller i accelereret fase eller blastkrise. • voksne patienter med nydiagnosticeret Philadelphiakromosom positiv akut lymfoblastær leukæmi (Ph+ ALL) integreret med kemoterapi. • voksne patienter med Ph+ ALL med tilbagefald eller refraktær sygdom som monoterapi. • voksne patienter med myelodysplastisk syndrom/ myeloproliferative sygdomme (MDS/ MPD) som er forbundet med platelet- derived growth factor receptor- omlejring (PDGFR- omlejring). • voksne patienter med refraktært hypereosiniphil syndrom (HES) og/ eller kronisk eosinofil leukæmi (CEL) uden FIP1L1- PDGFRα- omlejring.
Glivec is indicated for the treatment of • adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. • adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. • adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. • adult patients with relapsed or refractory Ph+ ALL as monotherapy. • adult patients with myelodysplastic/ myeloproliferative diseases (MDS/ MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. • adult patients with advanced hypereosinophilic syndrome (HES) and/ or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.